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Liver transplantation remains a controversial therapy for Neuroendocrine liver metastases (NLM), with coﬂicting suvival data
reported. The aim was to assess the evolution of outcomes for patients transplanted for NLM in the US, both before and after the
introduction of the MELD scoring system in 2002. The UNOS/OPTN database was reviewed to identify patients diagnosed with
NLM who subsequently underwent a liver transplantation from 1988 to March 2011 (n = 184); Patient survival was determined
using Kaplan-Meier methods and log-rank tests, and cox regression analysis was performed, using SPSS 15.0 (SPSS, Inc, Chicago,
IL). The overall NLM patient survivals in the pre-MELD era were 79.5%, 61.4%, and 49.2% at 1, 3, and 5 years, respectively. After
the introduction of the MELD score, NET/NLM patients had improved overall patient survivals at 1, 3, and 5 years of 84.7%, 65%,
and 57.8%. Patients transplanted after 2002 had an improved survival outcome. Notably, the overall patient survival for NET is
not signiﬁcantly diﬀerent when compared to the outcomes of patients transplanted for HCC, in the current era. This progress
acknowleges the signiﬁcant improvement in outcomes for NLM patients after liver transplantation and the potential for further
gain in the survival of otherwise nonsurgical, terminal patients.
1.Introduction
Neuroendocrine tumors (NETs) encompass a broad group
of neoplasms which originate from cells of the endocrine
and nervous systems and are of similar indolent character.
NETs are most commonly located in the gastrointestinal
system, including the pancreas, but also arise from many
other parts of the body. Patients with gastroenteropancreatic
neuroendocrine tumors commonly develop liver metastases,
which after protracted periods contribute towards morbidity
and mortality [1–4]. In fact, the majority of patients with
NET will have liver metastases discovered at the same time as
diagnosis[4,5].ThelivermetastasesassociatedwithNETare
typicallymultifocalanddiﬀuse,compromisingliveranatomy
andfunction.Withexcesshormoneproduction,thesemetas-
tases can lead to debilitating symptoms, in addition to end-
stage liver disease and death. Patients with neuroendocrine
liver metastases (NLM) respond well to surgical resection,
but, for patients who are ineligible due to widespread hepatic
involvement, orthotopic liver transplantation (OLT) can be
considered for curative therapy [4].
NLM is the only acceptable indication for OLT in the
setting of metastatic malignancies, enabled by their slow
growth rate and relatively low-grade malignancy. However,
OLT for NLM remains a controversial therapy as there is
conﬂicting actuarial data comparing outcomes of those
transplanted to those who receive other therapies, as well as
to others transplanted for diﬀerent indications. In fact, the
diﬀerence in 5-year survival between existing patient series
can range as wide as 17 to 47%, with one series of 10 patients
who received OLT for NET reporting a 90% 5-year survival
[2, 6–11]. The lack of consistency in the data is partially due
to the rarity of the disease and low incidence leading to small
sample sizes. For example, only 14 OLTs were performed for
NLM out of 28,665 OLTs performed in the United States in
2010 alone [6]. This is compounded with the wide variety of
treatment options and algorithms making standardized and
uniform protocols for this patient population diﬃcult.2 International Journal of Hepatology
Surgery is the only potential for cure in NET/NLM pa-
tients, currently, and also serves to prolong survival in
terminal disease. Complete surgical resection is an excellent
therapeutic modality, with acceptable outcomes and mini-
mal morbidity and mortality [12] though unfortunately is
available to only 10% of the neuroendocrine cancer patient
population [5, 7]. Excessive tumor burden in inaccessible
locations precludes complete resection for the majority.
Medical treatment options for patients who are not surgical
candidateshaveevolvedoverthelasttwodecades.This,along
with the development of liver-directed therapies including
ablative techniques, has expanded the treatment options for
the majority of patients with NET/NLM [13].
For those patients in whom surgical resection is not
indicated, symptomatic control and improved survival can
be obtained with functional hormonal blockade, liver-
directed therapies, and aggressive palliative treatments [8,
14]. Otherwise, OLT remains for the patients ineligible
for surgical resection or refractory to medical therapies.
Currently, patients with favorable biological features, includ-
ing well-diﬀerentiated tumors with low proliferation index
and overall stable disease without detectable extrahepatic
metastases, may be potentially cured by OLT. Therefore, only
a small subset of patients with NLM qualiﬁes for possible
OLT. Many transplant programs consider patients with NLM
for OLT if several criteria are met: the patient is not a
resection candidate, the primary disease is well identiﬁed
and completely resected, there is no evidence of extrahepatic
disease, the patient failed nonoperative therapies, and there
is evidence of disease stability for at least a year [9–11, 14].
In an eﬀort to assist in the selection of optimal NLM
patients who would beneﬁt from OLT, we aim to describe
the outcomes of these patients, as well as, explore possible
prognostic indicators to improve the allocation of a limited
organ supply. Minimal selection criteria exist for this patient
population and only recently are prognostic indicators being
identiﬁed. It is our goal to further characterize this popu-
lation in an eﬀort to improve the outcomes of those to be
transplanted in the future.
2.MaterialsandMethods
The United Network for Organ Transplantation/Organ Pro-
curement and Transplantation Network (UNOS/OPTN) da-
tabase is a national online database system to collect, store,
and publish all OPTN data pertaining to patients waiting for
and those who have received transplantation. This system
has documented every organ donation and transplantation
occurring in the US since 1986 [15]. The UNOS/OPTN
database was queried for this study. All OLTs performed
between September 1987 and March 2011 were reviewed.
Of 108,924 OLTs in the database, 184 were identiﬁed
to be secondary to neuroendocrine tumors. Since no
UNOS/OPTN diagnosis code for neuroendocrine tumor
exists, these cases were identiﬁed based on the diagnosis text
ﬁeld including “carcinoid”, “glucagonoma”, “gastrinoma”,
“insulinoma”, “islet cell tumor”, “pancreatic gastrinoma”,
“pancreatic islet cell tumor”, “VIPoma”, “Zollinger-Ellison’s
syndrome”, “neuroendocrine tumor”, or any combination
of those names with “metastatic”, “met”, or “malignant”.
The OLTs performed under these classiﬁcations are due
to an unspeciﬁed neuroendocrine liver metastatic disease.
Demographic information was analyzed including age, gen-
der, and ethnicity of recipient, along with age of donor.
Additionally, recipient characteristics such as creatinine,
international normalized ratio (INR), total bilirubin, and
albumin at time of transplant, days on the waitlist, model
for end-stage liver disease score, or pediatric model for end-
stage liver disease score (MELD/PELD), body mass index
(BMI), length of hospital stay (LOS) following transplant,
and ascites, encephalopathy, or dialysis prior to transplant
along with donor characteristics such as creatinine, aspartate
aminotransferase (AST), alanine aminotransferase (ALT),
and total bilirubin, and operative variables including cold
ischemia time (CIT) and warm ischemia time (WIT) were
analyzed. The education level of the recipient, whether the
recipient received multiple organs at time of transplant,
whether the recipient had a prior OLT, or whether the
recipient required retransplantation, were also included in
the analysis. MELD/PELD scores were introduced in 2002
which changed the paradigm of organ allocation from the
Child-Pugh Score and oﬀered a more precise allocation
model which accommodates for neoplastic disease. To assess
the evolution of OLT outcomes for NLM, the survivals
of patients transplanted before and after the introduction
of the MELD/PELD system in 2002 were assessed and
compared using the Kaplan-Meier and the log-rank tests.
Outcomes of all patients transplanted for NET/NLM were
then compared to patients transplanted for hepatocellular
carcinomaandfornonmalignantindicationstoassessoverall
survival experiences of NET/NLM patients relative to other
indications.
Time-to-event data were obtained from this database to
estimate post-OLT survival. Speciﬁcally, the time variable
was calculated as the length of time between transplantation
and either death or last known follow-up. An observation
was censored if the individual was alive at the last known
follow-up. Univariate and multivariate analyses were per-
formed by Cox’s regression and proportional hazards model,
and survival analysis was performed by the log-rank test and
the Kaplan-Meier test. Variables in the univariate analysis
with P value less than or equal to 0.200 were then tested in
the multivariate analysis using a step-by-step approach. A P
value less than or equal to 0.050 was considered statistically
signiﬁcance and indicative of independent prognostic factor.
All statistical functions performed on SPSS version 15.0
(IBM SPSS, Chicago, IL, USA).
3. Results
3.1. Patient Characteristics. From 1988 to March of 2011,
108,924 liver transplantations were performed in the US,
and, of those, 184 were performed for NET/NLM patients.
Descriptive analysis of the sample reveals a slight majority
of males at 54.1%, with an average age of 44.9 years (range
11–69 years), a mode of 56 years. Caucasians made up the
majority of recipients at 86.5%. The mean survival time was
41 months, though ranged from 0 to 253.3 months at theInternational Journal of Hepatology 3
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Figure 1: Liver transplantations for NET/NLM in USA. Note the
signiﬁcant increase in average number of transplantation which
occurred after the introduction of the MELD/PELD score in 2002.
time this analysis was completed. Average length of stay after
transplantation was 22.7 days, ranging 0–5.9 months. The
ﬁrst OLT for NLM included in the UNOS/OPTN database
was performed in 1988. The number of OLT performed
for the diagnosis of NET/NLM since then is separated into
the year when the transplant occurred and is illustrated in
Figure 1. Mean wait time on the transplant list for NET
patients was 5 months. The larger majority of this subgroup
received whole liver allografts, 89.7%, compared to split liver
allografts.TheLOSafterOLTrangedfrom15to52days,with
am e a no f2 3d a y s .
3.2. Introduction of the MELD/PELD Score. Figure 1 illus-
trates the distribution of liver transplantations which
occurred annually since 1988. 74 transplantations occurred
prior to the introduction of the MELD/PELD score in 2002.
Transplants in the pre-MELD era averaged approximately
4 transplants a year between 1993 and 2001. In the post-
MELD era, the average increase to 11.9 transplants annually
for NET/NLM. (Please note that at the time this paper
was written, 3 transplants occurred as of March of 2011.)
The Kaplan-Meier and log rank tests were used to compare
the survival experience of both the pre- and post-MELD
subgroups and found a statistically signiﬁcant diﬀerence
graphed in Figure 2 (P = 0.032). Patients transplanted
after the introduction of the MELD score had an improved
survival outcome as compared to patients transplanted
before 2002.
Overview of the patient sample reveals 86 patients who
ultimately expired after transplantation for NET/NLM.
Forty-sixofthosewerelistedtohavediedfromrecurrentand
metastatic disease. The remaining causes of death are as fol-
lows: sepsis/infections (9), unknown (8), lung/kidney/mul-
tiorgan failure (7), hemorrhage (2 GI, 2 intracranial), lym-
phoproliferative disorder (3), graft failure (3), cardiac arrest
(2), trauma (1), and hyperkalemia (1).
3.3. Patient and Allograft Survival. Patient and allograft sur-
vival of all NET/NLM patients ranged between 0 and 229.4
months. The mean overall patient survival was 91.9 months
(7.5 years) ± 10 months whereas the median overall patient
Overall patient survival of NET/NLM transplant patients
before and after MELD era
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Figure 2: Overall patient survival of NET/NLM transplant patients
in pre- and post-MELD era.
survival was 58.6 months ± 12.8 months. Overall patient
survivals were 79.5%, 61.4%, and 49.2% at 1, 3, and 5 years,
respectively (Figure 3). Allograft survival was 73.4%, 56.6%
and45.4%at1-,3-,and5-yearsurvivals,respectively,withan
overall mean allograft survival of 83.9 months ± 9.3 months
and overall median allograft survival of 47.1 months ± 8.2
months (Figure 3).
Kaplan-Meier log-rank analysis was also applied to over-
all patient survivals of patients transplanted for hepatocel-
lular Carcinoma and for nonmalignant indications. These
survivalcurveswerethencomparedtoallNET/NLMpatients
since 1988. NET/NLM patients had overall patient survivals
of 79.5%, 61.4%, and 49.2% at 1, 3, and 5 years, respectively.
This is compared to HCC patients, with 1-, 3-, and 5-year
survivals at 85.8%, 71.1%, and 60.6%, signiﬁcantly lower
with a P value of 0.002 (Figure 4). Overall patient survival of
those transplanted for nonmalignant indications was 85.2%,
78.3%, and 73.0% at 1-, 3-, and 5-year survivals, respectively,
signiﬁcantly better than patients transplanted for NET/NLM
(P<0.00) (Figure 4).
In light of the improved survival of NET patients trans-
planted after 2002, Kaplan-Meier log-rank analysis of over-
all patient survivals was also done for the three groups
(NET/NLM, HCC, nonmalignancy) of patients transplanted
after 2002. NET/NLM patients had overall patient survivals
at 1, 3, and 5 years of 84.7%, 65%, and 57.8%. This is
compared to HCC patients, with 1-, 3-, and 5-year survivals
at 88.0%, 74.3%, and 64.4%. As opposed to transplants
occurring prior to 2002, this diﬀerence in survival between
HCC and NET/NLM patients is no longer signiﬁcant (P =
0.109). Overall patient survival of those transplanted for
nonmalignant indications was 87.1%, 79.5%, and 73.7% at
1-, 3-, and 5-year survivals, respectively, still signiﬁcantly4 International Journal of Hepatology
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Figure 3: Neuroendocrine liver metastases: patient and allograft
survival after transplantation, 1988–2011.
NET versus HCC versus nonmalignant overall patient
survival after liver transplantation
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Figure 4: NET/NLM versus HCC versus nonmalignant patient sur-
vivals after transplantation, 1988–2011. NET/NLM versus HCC
(P = 0.002); NET/NLM versus nonmalignant (P ≤ 0.00).
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Figure 5: NET/NLM versus HCC versus nonmalignant patient sur-
vivals after transplantation, 2002–2011. NET/NLM versus HCC
(P = 0.109); NET/NLM versus nonmalignant (P = 0.002).
better than patients transplanted for NET/NLM (P = 0.002)
(Figure 5).
3.4.UnivariateandMultivariateAnalysisofClinicalVariables.
Several recipient and donor predictors were analyzed in
univariate analysis listed in Table 1. Of these variables, the
following approached the P value cutoﬀ for signiﬁcance of
<0.20 and were analyzed in the multivariate Cox regression
model.Severalprognosticfactorswerestatisticallysigniﬁcant
after multivariate analysis (Table 2).
For all patients transplanted for NLM since 1988, a high-
er albumin serum level at transplant was signiﬁcantly pro-
tective for patient survival (P = 0.033, OR = 0.45). A higher
donor creatinine at transplant had a negative impact on
allograft survival (P = 0.00, OR = 1.32), and, if the patient
requires retransplantation, the patient also had worse allo-
graft survival (P = 0.004, OR = 49.01; Table 2).
For patients transplanted for NLM after January 2002,
multivariate analysis revealed that patient survival was dele-
terious for higher recipient total bilirubin (P = 0.02, OR =
1.06) and higher donor creatinine (P = 0.004, OR = 1.29) at
time of OLT. A higher recipient albumin level at transplant
portended a protective eﬀect (P = 0.011, OR = 0.48) for
patient survival. Allograft survival was negatively impacted if
thepatientrequiredretransplantation(P<0.001,OR=35.9)
and by higher recipient total bilirubin (P = 0.02, OR = 1.06)
andhigherdonorcreatinineattimeoftransplant(P = 0.004,
OR = 1.31; Table 2).International Journal of Hepatology 5
Table 1: Clinical Variables used for univariate analysis with signif-
icance for patient and allograft survival. P values ≤ 0.2 were con-
sidered signiﬁcant for multivariate analysis and marked in bold for
clarity.
Univariate Cox regression
Clinical variables
Signiﬁcance
for patient
survival
Signiﬁcance
for allograft
survival
Recipient variables:
Age .477 .454
Gender .168 .157
Education level .174 .304
Ethnicity .007 .024
Body mass index .083 .043
MELD/PELD .000 .006
Days on waitlist .017 .033
Previously transplanted .782 .079
Patient requires
retransplantation .394 .000
Dialysis 1 week prior to OLT .006 .003
Encephalopathy .052 .135
Ascites .051 .088
Multiorgan recipient .110 .095
Type of allograft (Whole or Split) .244 .118
Creatinine at OLT .021 .082
Total bilirubin at OLT .008 .013
INR at OLT .546 .796
Albumin at OLT .000 .001
Cold ischemia time .574 .335
Warm ischemia time .650 .692
Length of postoperative stay .001 .002
Donor variables:
Age of donor .097 .037
Creatinine of donor .015 .067
Total bilirubin of donor .099 .095
AST of donor .639 .882
ALT of donor .447 .753
4. Discussion
The use of OLT for NLM remains a controversial topic, in
large part because of dismal outcomes, especially in early
evaluations of smaller series of patients. Over time, these
outcomes have slowly improved in further investigations,
with a growing number of larger series done mostly in
Europe.InouranalysisoftheUSAexperienceforOLTdueto
NLM, we have found that 5-year survival outcomes are less
favorable as compared to recipients of OLT for other causes,
but in-depth analysis reveals remarkable improvement in the
last decade. Of NET/NLM patients transplanted after 2002,
withtheintroductionofthemodel forend-stageliverdisease
(MELD)/pediatric end-stage liver disease (PELD) scoring
systems for organ allocation [16], the 5-year survival rate
increased from 49.2% to 57.8% as compared to all patients
Table 2: Multivariate Cox regression results of clinical variables
found to be signiﬁcant (P ≤ 0.05). ∗Signiﬁes percentage of sample
who required retransplantation.
Range Mean P value Change
in OR
Transplants after 1988
Patient survival
Albumin at
transplant 0.9–3.2 1.166 0.033 0.446
Allograft survival
Patient required
retransplant n/a 7.6%∗ <0.00 49.02
Donor creatinine 0.30–15.0 1.38 0.004 1.32
Transplants after 2002
Patient survival
Total bilirubin at
transplant 0.10–69.60 2.64 0.02 1.063
Albumin at
transplant 1.40–5.20 3.83 0.011 0.480
Donor creatinine 0.3–15.0 1.46 0.004 1.288
Allograft survival
Patient required
retransplant n/a 4.5%∗ <0.00 35.89
Total bilirubin at
transplant 0.10–69.60 2.64 0.019 1.060
Albumin at
transplant 1.40–5.20 3.83 0.006 0.455
Donor creatinine 0.3–15.0 1.46 0.004 1.308
transplanted since 1988. Notably, the overall patient survival
for NET/NLM is not signiﬁcantly diﬀerent from the 1-, 3-,
and 5-year outcomes of patients transplanted for HCC in
the current era, since the advent of the MELD/PELD scoring
system. This improvement acknowledges the potential for
further gain in the survival of a patient population that
would otherwise be considered for nonsurgical, palliative
care. The outcomes are not signiﬁcantly diﬀerent from
those of HCC patients, in whom liver transplantations are
performed regularly. OLT serves as a reasonable eﬀort in a
patient group otherwise desperate for aggressive treatment
options; the 5-year overall survival of patients with NLM on
supportive care alone is reported to range between 0% and
46% [5, 7, 11, 17, 18] and the 5-year disease-free survival
rate only at 24% [1]. Improvements in patient selection and
e v a l u a t i o n ,a sw e l la ss u r g i c a lt e c h n i q u ea n dp o s t o p e r a t i v e
care, have had a signiﬁcant eﬀect on this disease and its
outcomes.Asthemajorityofthesetransplantationsoccurred
after 2002, our analysis shows that we are transplanting
more patients with better outcomes over time. Olausson et
al. [19] and Le Treut et al. [2] have shown that increased
selectivity may be too speciﬁc, leaving out a number of
patients who have already exhausted all other treatment
options and who could otherwise beneﬁt from this life-
saving therapy. Olausson et al. transplanted 10 patients
with expanded criteria, including a higher proliferation rate
(measured by Ki67), large tumor burden, and higher age,6 International Journal of Hepatology
and were still able to show a 90% 5-year survival [19]. Le
Treut et al. developed a selection tool based on the patient’s
primary tumor location and liver size (not tumor burden),
which would have selected 70% of their 85-patient sample to
beneﬁt with a 68% ﬁve-year overall survival, inappropriately
excluding only 2 patients [2]. Thus, the importance of
precisely delineating the NET patient best suited for a liver
transplantation becomes paramount.
Our analysis allows for greater precision in selecting the
ideal NET/NLM patient for liver transplantation. From the
inception of the UNOS/OPTN database, our research shows
NET patient survival was aﬀected signiﬁcantly by albumin
and total bilirubin, with higher albumin and lower bilirubin
being protective. Allograft survival was negatively aﬀected
by the need for retransplantation and increased donor
creatinine. While the need for retransplantation cannot
be selected for, opting for patients with higher albumin
levels, lower total bilirubin and donors with lower creatinine
can improve both patient and allograft outcomes. While
recipient creatinine level has been shown to be a prognostic
indicator [3, 20], donor creatinine has not shown the
same for liver transplantation recipients at this time. We
hypothesize donors with elevated creatinine may have a
poorer clinical picture, and thus the donor creatinine may
act as a surrogate for the overall state of the liver allograft.
Veering away from recipients with higher total bilirubin may
help improve allocation eﬀorts toward NET/NLM patients
who would better beneﬁt from organ transplantation. Our
results corroborate with a large single-center series done by
Le Treut et al. [2], ﬁnding age as not a signiﬁcant variable in
survival, and this counters a large multivariate analysis done
by Lehnert [1]. Along with Le Treut et al., we found that
the requirement for early retransplantation was associated
with poorer outcomes and serves as a prognostic indicator
[2]. However, our analysis found that overall survival of
the UNOS/OPTN experience of those transplanted after
2002 is greater than that in their study, 57.8% versus 47%,
respectively [2].
Therapeutic approach to liver metastases of NET must
consider tumor distribution and bulk. Surgery is generally
considered as ﬁrst-line therapy, speciﬁcally liver resection
[21]. While liver transplantation may occasionally provide
for cure, it more often allows for symptomatic relief and
prolongs survival. It is thus reserved for cases in which liver
resection is not an option or for recurrent disease. Standard
therapies totreatneuroendocrine liver metastasesusuallyfall
into the category of liver-directed therapies. This method-
ology exploits the dual blood supply to the liver, from the
hepatic artery and portal vein, in order to control dis-
ease. Because of the higher recurrence rate of NET, these
techniques are better considered debulking modalities than
curativetherapy[22].Generalguidelinestodictatetreatment
options are dependent on tumor load, including location
and number, as well as size and invasiveness [13]. For fewer
lesions, local resection or thermal ablation is recommended.
For higher tumor loads or recurrent disease, hepatic artery
embolization and chemoembolization or radioembolization
is used [23]. Other therapies are nonsurgical, non-liver
directed therapies which includes chemotherapy and bio-
therapy and newer technologies directed at growth factors
and peptide receptors, as well as regulation of micro-RNA
pathways.
A weakness of this analysis is the inherent nature of
the UNOS/OPTN database, as it focuses on clinical data
pertinent to liver transplantation and not necessarily the
disease process of the liver. The location of the primary NET
and the histopathology have been shown to inﬂuence overall
survival [4, 11], along with concomitant upper abdominal
exenteration and presence of hepatomegaly [2]; however,
these data points were not included in the UNOS/OPTN
database as this database focuses on clinical variables as it
pertains to liver transplantation, not necessarily the disease
process leading to end-stage liver disease. Additionally,
time of diagnosis, presentation of symptoms, production
of hormones, and prior treatments utilized were also not
available, though quite pertinent in describing this patient
population. There is also evidence to suggest Ki67, and E-
Cadherin status aﬀects prognosis of NET patients [3, 10,
14, 19], but immunohistochemistry was not recorded. Lastly,
recurrence rate and disease-free survivals would allow a
more in-depth assessment of outcomes. These weaknesses
are acknowledged, and, while whole generalizations cannot
be made, it is important to note the breadth of this sample as
it illustrates the transplant experience of a national, and thus
larger, group of patients with the same rare disease, improv-
ing the power of the study. It is important to recognize that
liver transplantation for metastatic neuroendocrine tumors
is reserved for those with unresectable or refractory disease,
both implying a usually dismal prognosis without further
treatments. Survival time with patient status is present in
all 184 patients of our sample and thus serves as reliable
information on the survival experience of this rare and
desperate patient population.
While OLT oﬀers a potential for cure in these patients,
long-term survival remains lower than the 5-year survival of
patients transplanted for other diseases, both malignant and
nonmalignant. Manyhavequestionedwhethertheallocation
oflimitedresourcesiswarranted.Transplantingpatientswith
malignancies has been argued to be justiﬁable only if the
survival can be estimated to exceed 50% at 5 years [24].
Our analysis reveals that not only do NET/NLM patients
meet this criteria and do relatively well after transplant but
also they continue to improve over time and have survivals
not signiﬁcantly diﬀerent from HCC patients who are
transplanted. Considering the dismal prospects of a patient
population that is otherwise without much hope of long-
term survival and cure, the impact of these outcomes is
compelling [5]. There is promise in the progress of our care
for the NLM patient and liver transplantation, which oﬀers
us potential for improvement.
5. Conclusion
Understanding the limitations of the UNOS/OPTN database
and its focus on transplantations and the associated patient
and allograft outcomes, this analysis provides valuableInternational Journal of Hepatology 7
insight into patients with NLM and overall survivals after
liver transplantation.
While the 5-year survival of patients after OLT for NLM
is lower than that after OLT for non-malignant diseases, we
argue that the overall survival remains reasonable, exceeding
other estimations reported and is not signiﬁcantly different
from HCC outcomes. NET/NLM outcomes after OLT sur-
pass that of patients with untreated NLM left to its natural
progression. The signiﬁcant improvement in outcomes after
the introduction of the MELD/PELD scoring system rein-
forces the potential for gains in transplanting this patient
population, who have already failed or exhausted the litany
of therapeutic options dedicated to this disease process and
who are otherwise facing fatal prospects. This data helps
to characterize the NET/NLM patients who have beneﬁted
most from liver transplantation. Stratiﬁcation of variables
show requirement of a retransplant; decreased albumin level
of the recipient and elevated donor creatinine inﬂuence
the prognosis of the patient and the allograft after OLT in
patients with NLM. In this era of transplantation, we argue
the outcomes of liver transplantation for a carefully chosen
subset of neuroendocrine tumor patients are acceptable and
potentially life-saving.
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